A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Veliparib (Primary) ; Bevacizumab; Carboplatin; Doxorubicin liposomal
- Indications Adenocarcinoma; Clear cell sarcoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 21 Jul 2017 Status changed from active, no longer recruiting to completed.
- 02 Aug 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Feb 2017.
- 05 Jan 2016 Planned primar End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov.